Replicel Life Sciences Stock Current Asset
RP Stock | CAD 0.01 0.01 50.00% |
RepliCel Life Sciences fundamentals help investors to digest information that contributes to RepliCel Life's financial success or failures. It also enables traders to predict the movement of RepliCel Stock. The fundamental analysis module provides a way to measure RepliCel Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to RepliCel Life stock.
Other Current Assets is likely to climb to about 89.2 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 119.4 K in 2024. RepliCel | Current Asset |
RepliCel Life Sciences Company Current Asset Analysis
RepliCel Life's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
RepliCel Current Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for RepliCel Life is extremely important. It helps to project a fair market value of RepliCel Stock properly, considering its historical fundamentals such as Current Asset. Since RepliCel Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of RepliCel Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of RepliCel Life's interrelated accounts and indicators.
Click cells to compare fundamentals
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
Competition |
RepliCel Total Assets
Total Assets |
|
In accordance with the recently published financial statements, RepliCel Life Sciences has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all Canada stocks is 100.0% higher than that of the company.
RepliCel Life Current Valuation Drivers
We derive many important indicators used in calculating different scores of RepliCel Life from analyzing RepliCel Life's financial statements. These drivers represent accounts that assess RepliCel Life's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of RepliCel Life's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 6.1M | 6.2M | 7.5M | 3.2M | 3.9M | 3.7M | |
Enterprise Value | 6.6M | 6.2M | 7.3M | 2.8M | 4.7M | 8.4M |
RepliCel Fundamentals
Return On Asset | -1.53 | ||||
Profit Margin | 2.16 % | ||||
Operating Margin | (0.74) % | ||||
Current Valuation | 744.26 K | ||||
Shares Outstanding | 73.58 M | ||||
Shares Owned By Insiders | 59.39 % | ||||
Number Of Shares Shorted | 520 | ||||
Price To Earning | (1.05) X | ||||
Price To Sales | 2.08 X | ||||
Revenue | 353.74 K | ||||
Gross Profit | 353.74 K | ||||
EBITDA | (1.38 M) | ||||
Net Income | (311.73 K) | ||||
Cash And Equivalents | 1.16 M | ||||
Cash Per Share | 0.04 X | ||||
Total Debt | 813.19 K | ||||
Current Ratio | 2.09 X | ||||
Book Value Per Share | (0.07) X | ||||
Cash Flow From Operations | (1.41 M) | ||||
Short Ratio | 0.01 X | ||||
Earnings Per Share | (0.02) X | ||||
Target Price | 1.64 | ||||
Beta | 0.95 | ||||
Market Capitalization | 735.78 K | ||||
Total Asset | 287.79 K | ||||
Retained Earnings | (43.29 M) | ||||
Working Capital | (1.44 M) | ||||
Net Asset | 287.79 K |
About RepliCel Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze RepliCel Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RepliCel Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RepliCel Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RepliCel Stock Analysis
When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.